From Doctor to Entrepreneur Shaping the Future of Stem Cell Transplants

Interested in Working with us?Have a look here: https://www.passionfroot.me/startupradio Executive SummaryIn this episode, Joe interviews Andrea Tüttenberg, a female founder and professor at the University Clinic of Mainz. Andrea is the co-founder of Actitrex, a biotech startup focusing on immune cell therapy. She explains the journey from being a doctor and researcher to founding a company that develops treatments to minimize or avoid severe immune responses in patients undergoing stem cell transplantation and beyond. Andrea discusses the potential impact of their therapy, their need for funding, and the importance of talent acquisition. She also shares personal insights including the influence of her children and her dual roles as a doctor and entrepreneur. Follow Us on Social MediaIf you are listening to our content for the 2nd time please consider following us on social media. https://linktr.ee/startupradio Our Sponsor StartupravenThe best way to find investors and cooperation partners for early-stage startups. Sign up here: https://startupraven.com/ The FounderAndrea is a remarkable female founder and entrepreneur in the biotech industry. Andrea is the co-founder of ActiTrexx, a biotech startup focused on developing treatments for severe immune responses and immune-mediated diseases. With a background in medicine, Andrea has a strong foundation in clinical research and experience as a doctor, a professor at the University Clinic of Mainz, and a recipient of prestigious awards in the field of research and academia. Her journey from medical doctor to researcher and now entrepreneur is a testament to her passion for pushing the boundaries of medical science to create impactful treatments for patients in need. The StartupAndrea Tüttenberg is the co-founder of Actitrex, a pioneering biotech startup focused on developing a novel cell therapy to treat severe immune responses in patients undergoing stem cell transplantation for conditions such as leukemia. Actitrex is waiting for the first patient for its clinical trials. As the company gears up for the next stage of development, Actitrex is actively seeking series B funding to support its expansion and the advancement of its groundbreaking therapy. Find all links and show notes on our blog post: https://medium.com/startuprad-io/from-doctor-to-entrepreneur-shaping-the-future-of-stem-cell-transplants-54d02049dfd3

There are no comments yet.

Please log in to write the first comment.